[术前经导管肝动脉化疗栓塞术（TAE）对肝癌肿瘤切除患者预后的影响]
[Effects of preoperative transcatheter hepatic arterial chemoembolization (TAE) on the prognosis of patients with hepatic carcinoma undergoing tumor resection].
作者信息
Lu C, Peng S, Jiang X
机构信息
Department of Surgery, Second Affiliated Hospital, Zhejiang Medical University, Hangzhou.
出版信息
Zhonghua Wai Ke Za Zhi. 1996 Jul;34(7):413-5.
This study consists of 77 hepatocellular carcinoma patients. Twenty-six (Group A) received preoperative TAE and 51 did not (Group B). Group A and B were further divided into two subgroups according to their tumor size i.e. Group A1 and B1 (tumor size 3-8 cm); Group A2 and B2 (tumor size > 8 cm). The 1-, 2-, 3-year disease free survival rates were 50.0%, 33.3%, 16.6% for Group A1 and 72.7%, 54.2%, 39.7% for Group B1; 75.0%, 56.2%, 45.0% for Group A2 and 38.9%, 32.4%, 10.8% for Group B2 respectively. The 1-, 3-, 5-years survival rates were 85.7%, 31.2%, 0 for Group A1 and 84.8%, 58.7%, 27.9% for Group B1; 91.6%, 82.5%, 53.0% for Group A2 and 77.8%, 30.1%, 0 for Group B2 respectively. There were significant differences between Group A2 and B2 both in disease free survival rate and 5-year survival rate (P < 0.05). The results also demonstrated that the preoperative TAE did worsen the prognosis of patients with tumor size between 3-8 cm (Group A1) with disease free survival rate and 5-year survival rate shorter than that of Group A2.
本研究包含77例肝细胞癌患者。26例（A组）接受了术前肝动脉栓塞化疗（TAE），51例未接受（B组）。A组和B组根据肿瘤大小进一步分为两个亚组，即A1组和B1组（肿瘤大小3 - 8厘米）；A2组和B2组（肿瘤大小> 8厘米）。A1组1年、2年、3年无病生存率分别为50.0%、33.3%、16.6%，B1组分别为72.7%、54.2%、39.7%；A2组分别为75.0%、56.2%、45.0%，B2组分别为38.9%、32.4%、10.8%。A1组1年、3年、5年生存率分别为85.7%、31.2%、0，B1组分别为84.8%、58.7%、27.9%；A2组分别为91.6%、82.5%、53.0%，B2组分别为77.8%、30.1%、0。A2组和B2组在无病生存率和5年生存率方面均存在显著差异（P < 0.05）。结果还表明，术前肝动脉栓塞化疗确实使肿瘤大小在3 - 8厘米之间的患者（A1组）的预后恶化，其无病生存率和5年生存率低于A2组。
Zotero 插件